Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
Astrid A.M. van der Veldt(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Epie Boven(Amsterdam University Medical Centers), John B.A.G. Haanen(Leiden University Medical Center), Martijn R. Meijerink(Amsterdam University Medical Centers), Alfons J.M. van den Eertwegh(Amsterdam University Medical Centers)
Cited by 151
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
|The Lancet Oncology|2014|978
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
|Journal of Clinical Oncology|2013|799